Cyteir Therapeutics is a biotechnology business based in the US. Cyteir Therapeutics shares (CYT) are listed on the NASDAQ and all prices are listed in US Dollars. Cyteir Therapeutics employs 46 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $3.08 |
| 200-day moving average | $2.93 |
| Wall St. target price | $3.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.93 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Gross profit TTM | $-16,591,000 |
|---|---|
| Return on assets TTM | -14.5% |
| Return on equity TTM | -23.81% |
| Profit margin | 0% |
| Book value | $3.47 |
| Market Capitalization | $108.7 million |
TTM: trailing 12 months
We're not expecting Cyteir Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Cyteir Therapeutics's shares were split on a 2:1 basis on 17 September 2014 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cyteir Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cyteir Therapeutics shares which in turn could have impacted Cyteir Therapeutics's share price.
Over the last 12 months, Cyteir Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyteir Therapeutics's is 0.096. This would suggest that Cyteir Therapeutics's shares are less volatile than average (for this exchange).
To put Cyteir Therapeutics's beta into context you can compare it against those of similar companies.
Cyteir Therapeutics, Inc. , a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts. .
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
It can help reduce taxes owed, but it’s not for beginners.
Compare pros, cons, research tools and reviews for these two trading platforms.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.